AstraZenecaAstraZeneca PLC has reported that sales in the third quarter increased by 3 percent at CER, or 9 percent on an as reported basis. Sales in the US were unchanged, as the $141 million decline in sales of Toprol-XL from generic competition was offset by 5 percent growth in the rest of the US business. Sales in the Rest of World were up 6 percent. Sales in Established Markets were up 2 percent. The strong performance in Emerging Markets continues, with sales up 18 percent to $1,116 million, and this accounted for two thirds of the Rest of World sales increase.

Core operating profit in the third quarter was up 15 percent to $2,771 million, chiefly as a result of the sales increase, improvement in Core gross margin and R&D efficiencies. Reported operating profit increased by 19 percent to $2,522 million.

Core earnings per share in the third quarter were $1.32 compared with $1.04 in the third quarter 2007, a 20 percent increase at CER. In addition to the increase in Core operating profit, Core earnings per share benefited from lower net interest expense, the result of a fair value gain relating to certain long term bonds in issue, and a lower number of shares outstanding. Reported earnings per share in the third quarter were $1.20, an increase of 24 percent.

Nine Months
Sales for the nine months increased by 3 percent at CER, or 9 percent on an as reported basis. Sales in the US were unchanged as the sales decline in Toprol-XL was largely offset by the inclusion of MedImmune and modest growth in the rest of the US business. Sales in the Rest of World were up 6 percent. Sales in Established Markets were up 2 percent, with sales in Western Europe unchanged. Sales in Emerging Markets were up 16 percent.

Core operating profit increased by 10 percent to $8,273 million, as a result of improvements in gross margin and R&D efficiencies that more than offset the effect of lower other income and a slight increase in SG&A costs. Reported operating profit increased by 8 percent to $7,252 million.

Core earnings per share for the nine months were $3.85, an increase of 8 percent. Reported earnings per share for the nine months were $3.34, a 5 percent increase compared to last year.

Research and Development Update
A comprehensive update of the AstraZeneca R&D pipeline was presented in conjunction with the Half Year 2008 results and the pipeline table remains available on the Company's website, www.astrazeneca.com, under information for investors.

Learn how to replace the toxic products and medications in your home with over 215 healthier, all-natural alternatives
Learn how to replace the toxic products and medications in your home with over 215 healthier, all-natural alternatives